No clinical differences were found between patients with glomerulonephritis manifesting within 4 weeks after SARS-CoV-2 vaccination and those manifesting temporally unrelated to vaccination, according to a study published in Kidney International. Using a nationwide retrospective cohort and a case-cohort design, researchers examined the link between mRNA-based SARS-CoV-2 vaccination and new-onset glomerulonephritis. To calculate incidence of membranous nephropathy, immunoglobulin A nephropathy, minimal change disease, and pauci-immune necrotizing glomerulonephritis, they utilized data from pathology institutes that process kidney biopsies. Of 111 adult patients with newly diagnosed glomerulonephritis, 38.7% had received at least one vaccine dose before biopsy, compared with 39.5% of the general population. In vaccinated versus unvaccinated individuals, the estimated risk ratio for the development of new-onset, biopsy-proven glomerulonephritis was not noteworthy at 0.97 (95% CI, 0.66–1.42).
